MitoXcel geropeptides head to the World Congress as elamipretide wins a $101M XPRIZE milestone
Mitochondria-targeted therapeutics had a busy week. On September 22, 2026, Eos SENOLYTIX announced it will present its next-generation mitochondria-targeted MitoXcel geropeptides at the 17th World Congress on Targeting Mitochondria — building on the momentum of Stealth Bio's FORZINITY (elamipretide), the first mitochondria-targeted drug to receive FDA approval (accelerated, September 2025, for Barth syndrome).
What is the XPRIZE Healthspan connection?
The joint Mighty Therapeutics / University of Washington team won a Milestone 2 Award in the $101M XPRIZE Healthspan competition (announced August 2026) based on pilot data of elamipretide in older adults — a striking signal that mitochondria-targeted compounds are now competing on the world's largest longevity stage.
What does FORZINITY's approval actually cover?
Accelerated approval for Barth syndrome in patients weighing at least 30 kg, with a confirmatory trial still required. It is a landmark regulatory moment for mitochondrial medicine — not a blanket endorsement of elamipretide for anti-aging, fatigue or performance use.
How does this connect to mitochondrial health?
Elamipretide and MitoXcel act directly on mitochondrial membranes and energetics. The pipeline is moving from one approved indication toward broader aging biology — exactly the transition where evidence labels matter most.
Where the evidence stands
- Established: Elamipretide (FORZINITY) holds accelerated FDA approval for Barth syndrome — the first mitochondria-targeted drug approval.
- Investigational: MitoXcel geropeptides are pre-commercial; XPRIZE Healthspan pilot data in older adults are early and uncontrolled.
- Absent: No completed trial proves elamipretide extends healthspan or lifespan in healthy people.